| Symbol | CELU |
|---|---|
| Name | CELULARITY INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 170 PARK AVE, FLORHAM PARK, NJ 07932 |
| Telephone | (908) 768-2170 |
| Fax | — |
| — | |
| Website | https://www.celularity.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001752828 |
| Description | Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. Additional info from NASDAQ: |
New Form SCHEDULE 13D/A - Celularity Inc <b>Filed:</b> 2026-06-23 <b>AccNo:</b> 0001104659-26-076580 <b>Size:</b> 20 KB
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Delinquent. New value: Deficient and Delinquent.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Delinquent. New value: Deficient and Delinquent.
Read moreCelularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Delinquent.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Delinquent.
Read more(88% Positive) CELULARITY INC (CELU) Provides Update on execution for cellular medicine continues to grow
Read more